{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T02:54:35Z","timestamp":1789786475676,"version":"4.0.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,7,15]],"date-time":"2015-07-15T00:00:00Z","timestamp":1436918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2015,7,15]],"date-time":"2015-07-15T00:00:00Z","timestamp":1436918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Quantitation of huntingtin protein in the brain is needed, both as a marker of Huntington disease (HD) progression and for use in clinical gene silencing trials. Measurement of huntingtin in cerebrospinal fluid could be a biomarker of brain huntingtin, but traditional protein quantitation methods have failed to detect huntingtin in cerebrospinal fluid. Using micro-bead based immunoprecipitation and flow cytometry (IP-FCM), we have developed a highly sensitive mutant huntingtin detection assay. The sensitivity of huntingtin IP-FCM enables accurate detection of mutant huntingtin protein in the cerebrospinal fluid of HD patients and model mice, demonstrating that mutant huntingtin levels in cerebrospinal fluid reflect brain levels, increasing with disease stage and decreasing following brain huntingtin suppression. This technique has potential applications as a research tool and as a clinical biomarker.<\/jats:p>","DOI":"10.1038\/srep12166","type":"journal-article","created":{"date-parts":[[2015,7,15]],"date-time":"2015-07-15T10:43:45Z","timestamp":1436957025000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":100,"title":["Ultrasensitive measurement of huntingtin protein in cerebrospinal fluid demonstrates increase with Huntington disease stage and decrease following brain huntingtin suppression"],"prefix":"10.1038","volume":"5","author":[{"given":"Amber L.","family":"Southwell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen E.P.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tessa R.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas S.","family":"Caron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika B.","family":"Villanueva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyun","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Li Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Sturrock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blair R.","family":"Leavitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam G.","family":"Schrum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Hayden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,7,15]]},"reference":[{"key":"BFsrep12166_CR1","doi-asserted-by":"crossref","unstructured":"The Huntington\u2019s Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes. Cell 72, 971 (1993).","DOI":"10.1016\/0092-8674(93)90585-E"},{"key":"BFsrep12166_CR2","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/ajmg.b.30992","volume":"153B","author":"DR Langbehn","year":"2010","unstructured":"Langbehn, D. R., Hayden, M. R. & Paulsen, J. S. CAG-repeat length and the age of onset in Huntington disease (HD): A review and validation study of statistical approaches. Am. J. Med. Genet. B: Neuropsych. Genet. 153B, 397 (2010).","journal-title":"Am. J. Med. Genet. B: Neuropsych. Genet."},{"key":"BFsrep12166_CR3","doi-asserted-by":"publisher","first-page":"3498","DOI":"10.1073\/pnas.0308679101","volume":"101","author":"NS Wexler","year":"2004","unstructured":"Wexler, N. S. & Project, T. U. S.-V. C. R. Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington\u2019s disease age of onset. PNAS 101, 3498 (2004).","journal-title":"PNAS"},{"key":"BFsrep12166_CR4","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0092-8674(00)80623-6","volume":"101","author":"A Yamamoto","year":"2000","unstructured":"Yamamoto, A., Lucas, J. J. & Hen, R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington\u2019s disease. Cell 101, 57 (2000).","journal-title":"Cell"},{"key":"BFsrep12166_CR5","doi-asserted-by":"publisher","first-page":"5820","DOI":"10.1073\/pnas.0501507102","volume":"102","author":"SQ Harper","year":"2005","unstructured":"Harper, S. Q. et al. From the Cover: RNA interference improves motor and neuropathological abnormalities in a Huntington\u2019s disease mouse model. PNAS 102, 5820 (2005).","journal-title":"PNAS"},{"key":"BFsrep12166_CR6","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.bbrc.2006.02.141","volume":"343","author":"Y Machida","year":"2006","unstructured":"Machida, Y. et al. rAAV-mediated shRNA ameliorated neuropathology in Huntington disease model mouse. Biochem. Biophys. Res. Comm. 343, 190 (2006).","journal-title":"Biochem. Biophys. Res. Comm."},{"key":"BFsrep12166_CR7","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.ymthe.2005.05.006","volume":"12","author":"E Rodriguez-Lebron","year":"2005","unstructured":"Rodriguez-Lebron, E., Denovan-Wright, E. M., Nash, K., Lewin, A. S. & Mandel, R. J. Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6\/1 Huntington\u2019s disease transgenic mice. Mol. Ther. 12, 618 (2005).","journal-title":"Mol. Ther."},{"key":"BFsrep12166_CR8","doi-asserted-by":"publisher","first-page":"17204","DOI":"10.1073\/pnas.0708285104","volume":"104","author":"M DiFiglia","year":"2007","unstructured":"DiFiglia, M. et al. Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. PNAS 104, 17204 (2007).","journal-title":"PNAS"},{"key":"BFsrep12166_CR9","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.neures.2005.06.021","volume":"53","author":"Y-L Wang","year":"2005","unstructured":"Wang, Y.-L. et al. Clinico-pathological rescue of a model mouse of Huntington\u2019s disease by siRNA. Neurosci. R. 53, 241 (2005).","journal-title":"Neurosci. R."},{"key":"BFsrep12166_CR10","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/mt.2008.50","volume":"16","author":"NR Franich","year":"2008","unstructured":"Franich, N. R. et al. AAV vector-mediated RNAi of mutant huntingtin expression is neuroprotective in a novel genetic rat model of Huntington\u2019s disease. Mol. Ther. 16, 947 (2008).","journal-title":"Mol. Ther."},{"key":"BFsrep12166_CR11","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1002\/ana.21569","volume":"65","author":"V Drouet","year":"2009","unstructured":"Drouet, V. et al. Sustained effects of nonallele-specific huntingtin silencing. Ann. Neurol. 65, 276 (2009).","journal-title":"Ann. Neurol."},{"key":"BFsrep12166_CR12","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1038\/mt.2009.17","volume":"17","author":"RL Boudreau","year":"2009","unstructured":"Boudreau, R. L. et al. Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in huntington\u2019s disease mice. Mol. Ther. 17, 1053 (2009).","journal-title":"Mol. Ther."},{"key":"BFsrep12166_CR13","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.neuron.2012.05.009","volume":"74","author":"HollyB Kordasiewicz","year":"2012","unstructured":"Kordasiewicz, Holly B. et al. Sustained therapeutic reversal of Huntington\u2019s disease by transient repression of huntingtin synthesis. Neuron 74, 1031 (2012).","journal-title":"Neuron"},{"key":"BFsrep12166_CR14","unstructured":"Khoshnan, A., Southwell, A., Bugg, C., Ko, J. & Patterson, P. in Neurobiology of Huntington\u2019s Disease: Applications to Drug Discovery, edited by D. C. Lo & R. E. Hughes (CRC Press, Boca Raton, 2011)."},{"key":"BFsrep12166_CR15","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1002\/cne.21515","volume":"505","author":"A Reiner","year":"2007","unstructured":"Reiner, A. et al. R6\/2 neurons with intranuclear inclusions survive for prolonged periods in the brains of chimeric mice. J. Comp. Neurol. 505, 603 (2007).","journal-title":"J. Comp. Neurol."},{"key":"BFsrep12166_CR16","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1038\/mt.2011.201","volume":"19","author":"JB Carroll","year":"2011","unstructured":"Carroll, J. B. et al. Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene \/ Allele-specific silencing of mutant huntingtin. Mol. Ther. 19, 2178 (2011).","journal-title":"Mol. Ther."},{"key":"BFsrep12166_CR17","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1093\/hmg\/dds397","volume":"22","author":"AL Southwell","year":"2013","unstructured":"Southwell, A. L. et al. A fully humanized transgenic mouse model of Huntington disease. Hum. Mol. Genet. 22, 18 (2013).","journal-title":"Hum. Mol. Genet."},{"key":"BFsrep12166_CR18","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ab.2009.08.001","volume":"395","author":"A Weiss","year":"2009","unstructured":"Weiss, A. et al. Single-step detection of mutant huntingtin in animal and human tissues: A bioassay for Huntington\u2019s disease. Anal. Biochem. 395, 8 (2009).","journal-title":"Anal. Biochem."},{"key":"BFsrep12166_CR19","doi-asserted-by":"publisher","first-page":"e96854","DOI":"10.1371\/journal.pone.0096854","volume":"9","author":"D Macdonald","year":"2014","unstructured":"Macdonald, D. et al. Quantification assays for total and polyglutamine-expanded huntingtin proteins, PLoS ONE 9, e96854 (2014).","journal-title":"PLoS ONE"},{"key":"BFsrep12166_CR20","doi-asserted-by":"publisher","first-page":"pl2","DOI":"10.1126\/stke.3892007pl2","volume":"2007","author":"AG Schrum","year":"2007","unstructured":"Schrum, A. G. et al. High-sensitivity detection and quantitative analysis of native protein-protein interactions and multiprotein complexes by flow cytometry. Sci. Signal. 2007, pl2 (2007).","journal-title":"Sci. Signal."},{"key":"BFsrep12166_CR21","doi-asserted-by":"publisher","first-page":"e45722","DOI":"10.1371\/journal.pone.0045722","volume":"7","author":"SEP Smith","year":"2012","unstructured":"Smith, S. E. P. et al. IP-FCM measures physiologic protein-protein interactions modulated by signal transduction and small-molecule drug inhibition. PLoS ONE 7, e45722 (2012).","journal-title":"PLoS ONE"},{"key":"BFsrep12166_CR22","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S0361-9230(01)00599-8","volume":"56","author":"J Ko","year":"2001","unstructured":"Ko, J., Ou, S. & Patterson, P. H. New anti-huntingtin monoclonal antibodies: implications for huntingtin conformation and its binding proteins. Brain Res. Bull. 56, 319 (2001).","journal-title":"Brain Res. Bull."},{"key":"BFsrep12166_CR23","doi-asserted-by":"publisher","first-page":"7862","DOI":"10.1523\/JNEUROSCI.22-18-07862.2002","volume":"22","author":"CL Wellington","year":"2002","unstructured":"Wellington, C. L. et al. Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington\u2019s disease. J. Neurosci. 22, 7862 (2002).","journal-title":"J. Neurosci."},{"key":"BFsrep12166_CR24","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/0092-8674(95)90542-1","volume":"81","author":"J Nasir","year":"1995","unstructured":"Nasir, J. et al. Targeted disruption of the Huntington\u2019s disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell 81, 811 (1995).","journal-title":"Cell"},{"key":"BFsrep12166_CR25","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/ng1095-155","volume":"11","author":"S Zeitlin","year":"1995","unstructured":"Zeitlin, S., Liu, J. P., Chapman, D. L., Papaioannou, V. E. & Efstratiadis, A. Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington\u2019s disease gene homologue. Nat. genet. 11, 155 (1995).","journal-title":"Nat. genet."},{"key":"BFsrep12166_CR26","doi-asserted-by":"publisher","first-page":"6182","DOI":"10.1523\/JNEUROSCI.0857-08.2008","volume":"28","author":"M Gray","year":"2008","unstructured":"Gray, M. et al. Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J. Neurosci. 28, 6182 (2008).","journal-title":"J. Neurosci."},{"key":"BFsrep12166_CR27","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/12703","volume":"23","author":"F Tronche","year":"1999","unstructured":"Tronche, F. et al. Disruption of the glucocorticoid receptor gene in the nervous system results in reduced anxiety. Nat. Genet. 23, 99 (1999).","journal-title":"Nat. Genet."},{"key":"BFsrep12166_CR28","doi-asserted-by":"publisher","first-page":"10855","DOI":"10.1074\/jbc.M804813200","volume":"284","author":"T Ratovitski","year":"2009","unstructured":"Ratovitski, T. et al. Mutant huntingtin n-terminal fragments of specific size mediate aggregation and toxicity in neuronal cells. J. Biol. Chem. 284, 10855 (2009).","journal-title":"J. Biol. Chem."},{"key":"BFsrep12166_CR29","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1523\/JNEUROSCI.21-06-01830.2001","volume":"21","author":"LM Mende-Mueller","year":"2001","unstructured":"Mende-Mueller, L. M., Toneff, T., Hwang, S.-R., Chesselet, M.-F. & Hook, V. Y. H. Tissue-specific proteolysis of huntingtin (htt) in human brain: evidence of enhanced levels of N- and C-terminal htt fragments in Huntington\u2019s disease striatum. J. Neurosci. 21, 1830 (2001).","journal-title":"J. Neurosci."},{"key":"BFsrep12166_CR30","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1093\/hmg\/ddg169","volume":"12","author":"EJ Slow","year":"2003","unstructured":"Slow, E. J. et al. Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum. Mol. Genet. 12, 1555 (2003).","journal-title":"Hum. Mol. Genet."},{"key":"BFsrep12166_CR31","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1038\/mt.2014.153","volume":"22","author":"AL Southwell","year":"2014","unstructured":"Southwell, A. L. et al. In vivo evaluation of candidate allele-specific mutant huntingtin gene silencing antisense oligonucleotides. Mol. Ther. 22, 2093 (2014).","journal-title":"Mol. Ther."},{"key":"BFsrep12166_CR32","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1523\/JNEUROSCI.5473-08.2009","volume":"29","author":"RK Graham","year":"2009","unstructured":"Graham, R. K. et al. Differential susceptibility to excitotoxic stress in YAC128 mouse models of Huntington disease between initiation and progression of disease. J. Neurosci. 29, 2193 (2009).","journal-title":"J. Neurosci."},{"key":"BFsrep12166_CR33","first-page":"e2066","volume":"46","author":"TR Davis","year":"2010","unstructured":"Davis, T. R. & Schrum, A. G. IP-FCM: Immunoprecipitation detected by flow cytometry. J. Vis. Exp. 46, e2066 (2010).","journal-title":"J. Vis. Exp."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep12166.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep12166","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep12166.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T15:01:58Z","timestamp":1672930918000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep12166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,15]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015,12,18]]}},"alternative-id":["BFsrep12166"],"URL":"https:\/\/doi.org\/10.1038\/srep12166","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,15]]},"assertion":[{"value":"5 February 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12166"}}